ALD Connect

Clinical Trials & ALD Research

Research helps us learn more about adrenoleukodystrophy and determine whether new treatments are safe and effective.

Please explore below to find the latest information on ALD research and ALD clinical trial developments.

Clinical Trials

Clinical trials are a critical part of advancing treatments and improving outcomes for patients with adrenoleukodystrophy (ALD). At ALD Connect, we work closely with researchers, healthcare providers, and the patient community to promote participation in clinical trials that aim to find new therapies and better understand the disease. By enrolling in clinical trials, patients and caregivers can play a vital role in the development of treatments that could benefit the ALD community for generations to come.

Learn More

Emerging Investigator Program

Our Emerging Investigator program started in 2022. ALD Connect strives to engage the next generation of researchers and accelerate ALD research. This program helps us achieve both goals.

Learn More

The Grey Zone

The Grey Zone is an important community-wide ALD research project. It focuses on investigating C26:0 lysoPC levels that are in “The Grey Zone”, which is the range in between the reference controls and the established ALD disease range.

Learn More

Useful Links

Clinical Trials
Clinical Trials
The Grey Zone
The Grey Zone
Emerging Investigators
Emerging Investigators

Donate to ALD Connect

Your support is crucial to advancing life-saving research and providing essential resources for individuals affected by adrenoleukodystrophy. Donations to ALD Connect directly fund scientific research, improving patient care, and expanding our education and support services.

Donate